The DOI matches its Crossref record.
Serum Tryptase Measurements in Patients with Myelodysplastic Syndromes
Abstract
Abnormal differentiation and maturation of hemopoietic cells are characteristic features of myelodysplastic syndromes (MDS). Tryptases (alpha- and beta-type) are lineage-restricted serine proteases primarily expressed in mast cells (MC). We have analyzed expression of tryptase in 89 de novo MDS patients (refractory anemia (RA), n = 30; RA with ringed sideroblasts (RARS), n = 21; RA with excess of blasts (RAEB/RAEB-t), n = 27; chronic myelomonocytic leukemia (CMML), n = 11). Serum levels of total tryptase (alpha - protryptase + beta - tryptase) were measured by FIA. The numbers of tryptase+ cells were determined in paraffin-embedded bone marrow (bm) sections by immunohistochemistry and morphometry. In healthy individuals, serum total tryptase levels ranged between < 1 and 15 ng/ml (5.6 +/- 2.8 ng/ml). Tryptase levels of > 20 ng/ml were detected in 5/22 patients with RA (22.7%), 4/17 with RARS (23.5%), 0/16 with RAEB/RAEB-t, and 3/8 with CMML (37.5%). Thus, serum tryptase concentrations were higher in RA (16.6 +/- 14.3 ng/ml), RARS (12.9 +/- 8.2), and CMML (16.5 +/- 7.6) compared to RAEB/-t (8.7 +/- 3.8). By morphometry, elevated numbers of tryptase+ bm cells were detected in all MDS groups (RA: 139 +/- 131; RARS: 118 +/- 98; RAEB/RAEB-t: 80 +/- 79; CMML: 105 +/- 114 cells/mm2) compared to controls (54 +/- 51 cells/mm2). As assessed by Northern blotting and protein analysis, bm cells in MDS primarily produced alpha-(pro)tryptase, but little or no beta-tryptase. Together, our data show that elevated levels of tryptase are detectable in a group of patients with MDS probably because of an increase in neoplastic (mast) cells producing the enzyme(s). In addition, serum tryptase levels appear to correlate with MDS variants. Follow up studies should clarify whether an elevated tryptase concentration in MDS is of prognostic significance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“over 30% of all patients with myeloid neoplasms, including mastocytosis, have elevated basal tryptase levels.”
From Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome (2019) · cites this paper as [25]
In the citing paper
“the baseline level of tryptase varies depending on the underlying disease and the genetic background.”
From Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome (2019) · cites this paper as [25]
In the citing paper
“Thus, a number of genetic, inflammatory, and neoplastic conditions are associated with an increased basal serum tryptase level.”
From Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome (2019) · cites this paper as [25]
In the citing paper
“These include tryptase gene replications such as hereditary alpha tryptasemia; chronic infections, such as helminth infections; renal insufficiency – especially hemodialysis patients; and myeloid neoplasms, including myelodysplastic syndromes, SM, acute myeloid leukemia, chronic myeloid leukemia (CML), and chronic eosinophilic leukemia [25–33].”
From Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome (2019) · cites this paper as [25]
In the citing paper
“when taking the 11.4 threshold as denominator, an increased basal tryptase level is found frequently in otherwise healthy individuals (roughly 5–10% of the general population), in diverse reactive states, and in hematologic disorders, especially in myeloid malignancies (roughly 20–30%; Table 2) [25–31].”
From Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome (2019) · cites this paper as [25]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Still being checked.
Cited by
Valent, P., Akin, C., Escribano, L., Födinger, M., Hartmann, K., Brockow, K., Castells, M., Sperr, W. R., Kluin‐Nelemans, H. C., Hamdy, N. A. T., et al. (2007) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2007.01807.x · Cited by 750
Self-citationValent, P., Horny, H.-P., Bennett, J. M., Fonatsch, C., Germing, U., Greenberg, P., Haferlach, T., Haase, D., Kolb, H.-J., Krieger, O., et al. (2007) · Leukemia Research · doi:10.1016/j.leukres.2006.11.009 · Cited by 513
Self-citationDiagnostic Value of Tryptase in Anaphylaxis and Mastocytosis
Schwartz, L. B. (2006) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2006.05.010 · Cited by 477
Self-citationRuëff, F., Przybilla, B., Biló, M. B., Müller, U., Scheipl, F., Aberer, W., Birnbaum, J., Bodzenta-Lukaszyk, A., Bonifazi, F., Bucher, C., et al. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.08.027 · Cited by 430
Anaphylaxis During the Perioperative Period
Hepner, D. L., & Castells, M. C. (2003) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000082993.84883.7d · Cited by 375
Metadata
- Authors
- Sperr, W. R., Stehberger, B., Wimazal, F., Baghestanian, M., Schwartz, L. B., Kundi, M., Semper, H., Jordan, J.-H., Chott, A., Drach, J., Jäger, U., Geissler, K., Greschniok, A., Horny, H.-P., Lechner, K., & Valent, P.
- Affiliations
- University of Vienna (AT)
- University of Tübingen (DE)
- Virginia Commonwealth University (US)
- Venue
- Leukemia & Lymphoma
- Publisher
- Informa UK Limited
- Published
- 2002-01
- Volume
- 43
- Issue
- 5
- Pages
- 1097-1105
- ISSN
- 1026-8022 (ISSN-L)
- 1042-8194
- 1029-2403
- OpenAlex
- W1682346499
- Cited by
- 83
- References
- 0
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 8 · 2023: 2 · 2022: 4 · 2021: 3 · 2020: 3 · 2019: 4 · 2017: 1 · 2016: 1 · 2014: 2 · 2013: 2 · 2012: 8
- FWCI
- 2.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Leukemia & lymphoma/Leukemia and lymphoma (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (AI20487)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (AR45441, R01AR045441)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Keywords
- myelodysplastic syndrome, serum tryptase, beta-tryptase, mast cells, refractory anemia, chronic myelomonocytic leukemia, bone marrow mast cells, serine protease, disease biomarkers, myeloproliferative neoplasms
- MeSH terms
- Adult, Aged, Aged, 80 and over, Chromosomes, Human, Pair 8, Humans, Middle Aged, Myelodysplastic Syndromes, RNA, Messenger, Serine Endopeptidases, Trisomy, In Situ Hybridization, Fluorescence, Tryptases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Serum Tryptase Measurements in Patients with Myelodysplastic Syndromes. https://app.cochat.ai/papers/10.1080/10428190290021470
- The paper
- Sperr, W. R., Stehberger, B., Wimazal, F., Baghestanian, M., Schwartz, L. B., Kundi, M., Semper, H., Jordan, J.-H., Chott, A., Drach, J., Jäger, U., Geissler, K., Greschniok, A., Horny, H.-P., Lechner, K., & Valent, P. (2002). Serum Tryptase Measurements in Patients with Myelodysplastic Syndromes. Leukemia & Lymphoma. https://doi.org/10.1080/10428190290021470
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.